NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors (original) (raw)

• Wen, P.Y. & Kesari, S. Malignant gliomas in adults. N. Engl. J. Med. 359, 492–507 (2008).
  Article CAS PubMed Google Scholar
• Chiocca, E.A. Oncolytic viruses. Nat. Rev. Cancer 2, 938–950 (2002).
  Article PubMed CAS Google Scholar
• Markert, J.M. et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol. Ther. 17, 199–207 (2009).
  Article CAS PubMed Google Scholar
• Chiocca, E.A. The host response to cancer virotherapy. Curr. Opin. Mol. Ther. 10, 38–45 (2008).
  PubMed Google Scholar
• Fulci, G. et al. Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res. 67, 9398–9406 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Ikeda, K. et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat. Med. 5, 881–887 (1999).
  Article CAS PubMed Google Scholar
• Fulci, G. et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc. Natl. Acad. Sci. USA 103, 12873–12878 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Kurozumi, K. et al. Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J. Natl. Cancer Inst. 99, 1768–1781 (2007).
  Article CAS PubMed Google Scholar
• Friedman, A., Tian, J.P., Fulci, G., Chiocca, E.A. & Wang, J. Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. Cancer Res. 66, 2314–2319 (2006).
  Article CAS PubMed Google Scholar
• Wakimoto, H., Fulci, G., Tyminski, E. & Chiocca, E.A. Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis. Gene Ther. 11, 214–223 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Altomonte, J. et al. Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells. Cancer Gene Ther. 16, 266–278 (2009).
  Article CAS PubMed Google Scholar
• Todo, T., Martuza, R.L., Rabkin, S.D. & Johnson, P.A. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc. Natl. Acad. Sci. USA 98, 6396–6401 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Varghese, S., Rabkin, S.D., Nielsen, P.G., Wang, W. & Martuza, R.L. Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung. Clin. Cancer Res. 12, 2919–2927 (2006).
  Article CAS PubMed Google Scholar
• Farrell, C.J. et al. Combination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells. Clin. Cancer Res. 14, 7711–7716 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Hellums, E.K. et al. Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neuro-oncol. 7, 213–224 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Prestwich, R.J. et al. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum. Gene Ther. 20, 1119–1132 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Stanford, M.M., Breitbach, C.J., Bell, J.C. & McFadden, G. Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes? Curr. Opin. Mol. Ther. 10, 32–37 (2008).
  CAS PubMed Google Scholar
• Errington, F. et al. Reovirus activates human dendritic cells to promote innate antitumor immunity. J. Immunol. 180, 6018–6026 (2008).
  Article CAS PubMed Google Scholar
• Prestwich, R.J. et al. Reciprocal human dendritic cell–natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J. Immunol. 183, 4312–4321 (2009).
  Article CAS PubMed Google Scholar
• Kottke, T. et al. Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer. Mol. Ther. 16, 1910–1918 (2008).
  Article CAS PubMed Google Scholar
• Kottke, T. et al. Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated treg modulation and interleukin-2. Clin. Cancer Res. 15, 561–569 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Derubertis, B.G. et al. Cytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell–dependent mechanisms. Cancer Gene Ther. 14, 590–597 (2007).
  Article CAS PubMed Google Scholar
• Chisholm, S.E., Howard, K., Gómez, M.V. & Reyburn, H.T. Expression of ICP0 is sufficient to trigger natural killer cell recognition of herpes simplex virus-infected cells by natural cytotoxicity receptors. J. Infect. Dis. 195, 1160–1168 (2007).
  Article CAS PubMed Google Scholar
• Kambara, H., Okano, H., Chiocca, E.A. & Saeki, Y. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res. 65, 2832–2839 (2005).
  Article CAS PubMed Google Scholar
• Aghi, M., Visted, T., Depinho, R.A. & Chiocca, E.A. Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. Oncogene 27, 4249–4254 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Hayakawa, Y. & Smyth, M.J. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J. Immunol. 176, 1517–1524 (2006).
  Article CAS PubMed Google Scholar
• Dalton, D.K. et al. Multiple defects of immune cell function in mice with disrupted interferon-γ genes. Science 259, 1739–1742 (1993).
  Article CAS PubMed Google Scholar
• Yoshino, H. et al. Natural killer cell depletion by anti-asialo GM1 antiserum treatment enhances human hematopoietic stem cell engraftment in NOD/Shi-scid mice. Bone Marrow Transplant. 26, 1211–1216 (2000).
  Article CAS PubMed Google Scholar
• Randolph, G.J., Jakubzick, C. & Qu, C. Antigen presentation by monocytes and monocyte-derived cells. Curr. Opin. Immunol. 20, 52–60 (2008).
  Article CAS PubMed Google Scholar
• Savarin, C. & Bergmann, C.C. Neuroimmunology of central nervous system viral infections: the cells, molecules and mechanisms involved. Curr. Opin. Pharmacol. 8, 472–479 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Weiner, N.E. et al. A syngeneic mouse glioma model for study of glioblastoma therapy. J. Neuropathol. Exp. Neurol. 58, 54–60 (1999).
  Article CAS PubMed Google Scholar
• Taylor, M.A., Ward, B., Schatzle, J.D. & Bennett, M. Perforin- and Fas-dependent mechanisms of natural killer cell–mediated rejection of incompatible bone marrow cell grafts. Eur. J. Immunol. 32, 793–799 (2002).
  Article CAS PubMed Google Scholar
• Trotta, R. et al. Dependence of both spontaneous and antibody-dependent, granule exocytosis-mediated NK cell cytotoxicity on extracellular signal-regulated kinases. J. Immunol. 161, 6648–6656 (1998).
  CAS PubMed Google Scholar
• Castriconi, R. et al. NK cells recognize and kill human glioblastoma cells with stem cell–like properties. J. Immunol. 182, 3530–3539 (2009).
  Article CAS PubMed Google Scholar
• Wu, A. et al. Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy. J. Neurooncol. 83, 121–131 (2007).
  Article CAS PubMed Google Scholar
• Brandt, C.S. et al. The B7 family member B7–H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J. Exp. Med. 206, 1495–1503 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Orange, J.S. Human natural killer cell deficiencies. Curr. Opin. Allergy Clin. Immunol. 6, 399–409 (2006).
  Article PubMed Google Scholar
• Altomonte, J. et al. Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo. Mol. Ther. 16, 146–153 (2008).
  Article CAS PubMed Google Scholar
• Galivo, F. et al. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus. Hum. Gene Ther. 21, 439–450 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Galivo, F. et al. Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. Gene Ther. 17, 158–170 (2010).
  Article CAS PubMed Google Scholar
• Marques, C.P., Hu, S., Sheng, W. & Lokensgard, J.R. Microglial cells initiate vigorous yet non-protective immune responses during HSV-1 brain infection. Virus Res. 121, 1–10 (2006).
  Article CAS PubMed Google Scholar
• Yu, J. et al. CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK cell subsets. Blood 115, 274–281 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Lundberg, P. et al. A locus on mouse chromosome 6 that determines resistance to herpes simplex virus also influences reactivation, while an unlinked locus augments resistance of female mice. J. Virol. 77, 11661–11673 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Arnon, T.I., Markel, G. & Mandelboim, O. Tumor and viral recognition by natural killer cells receptors. Semin. Cancer Biol. 16, 348–358 (2006).
  Article CAS PubMed Google Scholar
• Bloushtain, N. et al. Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46. J. Immunol. 173, 2392–2401 (2004).
  Article CAS PubMed Google Scholar
• Ferlazzo, G. et al. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J. Exp. Med. 195, 343–351 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Arnon, T.I. et al. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat. Immunol. 6, 515–523 (2005).
  Article CAS PubMed Google Scholar
• Degli-Esposti, M.A. & Smyth, M.J. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat. Rev. Immunol. 5, 112–124 (2005).
  Article CAS PubMed Google Scholar
• Pogge von Strandmann, E. et al. Human leukocyte antigen-B–associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 27, 965–974 (2007).
  Article CAS PubMed Google Scholar
• Sivori, S. et al. NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur. J. Immunol. 29, 1656–1666 (1999).
  Article CAS PubMed Google Scholar
• Giannini, C. et al. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro-oncol. 7, 164–176 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Reilly, K.M., Loisel, D.A., Bronson, R.T., McLaughlin, M.E. & Jacks, T. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat. Genet. 26, 109–113 (2000).
  Article CAS PubMed Google Scholar
• Shultz, L.D. et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2Rγ null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 174, 6477–6489 (2005).
  Article CAS PubMed Google Scholar
• Yu, J. et al. NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human. J. Clin. Invest. 121, 1456–1470 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Ghiasi, H., Cai, S., Perng, G.C., Nesburn, A.B. & Wechsler, S.L. The role of natural killer cells in protection of mice against death and corneal scarring following ocular HSV-1 infection. Antiviral Res. 45, 33–45 (2000).
  Article CAS PubMed Google Scholar
• Gazit, R. et al. Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1. Nat. Immunol. 7, 517–523 (2006).
  Article CAS PubMed Google Scholar
• Marques, C.P. et al. Prolonged microglial cell activation and lymphocyte infiltration following experimental herpes encephalitis. J. Immunol. 181, 6417–6426 (2008).
  Article CAS PubMed Google Scholar
• Vitale, M. et al. NK-dependent DC maturation is mediated by TNFα and IFNγ released upon engagement of the NKp30 triggering receptor. Blood 106, 566–571 (2005).
  Article CAS PubMed Google Scholar
• Walzer, T. et al. Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46. Proc. Natl. Acad. Sci. USA 104, 3384–3389 (2007).
  Article CAS PubMed PubMed Central Google Scholar